| 97 blog results |
|
-
Contributor: Pharmatching.com Blog
Contributor: 08/31/2011 12:00:00 AM EDT
Oxford BioMedica reports advances in gene therapy Published with kind permission of MEDNOUS Oxford BioMedica Plc said that recent, promising data from an ongoing Phase 1/2 study of its gene therapy, ProSavin, support the therapy’s potential as a treatment for the motor symptoms of Parkinson’s disease. read more
-
Contributor: Pharmatching.com Blog
Contributor: 08/19/2011 12:00:00 AM EDT
SkyePharma outlook linked to Flutiform approval Published with kind permission of MEDNOUS. SkyePharma PC said regulatory clearance in Europe of its asthma drug, Flutiform, is still pivotal to its long-term growth. read more
-
Contributor: Pharmatching.com Blog
Contributor: 08/17/2011 12:00:00 AM EDT
Great project: Lab in a cell A group of young and enthusiasthic Freiburger scientists aims to transform protein expression in bacterial systems into an elegant, fast and affordable process. read more
-
Contributor: Pharmatching.com Blog
Contributor: 08/02/2011 12:00:00 AM EDT
Core products sustain UCB at mid-year Published with kind permission of MEDNOUS. Three core products continued to drive growth at UCB SA during the first half of 2011 setting the Belgian company on course for revenue of about €3. read more
-
Contributor: Pharmatching.com Blog
Contributor: 07/29/2011 12:00:00 AM EDT
AstraZeneca raises EPS guidance; to increase share repurchases Published with kind permission of MEDNOUS AstraZeneca Plc has again raised its target for earnings per share in 2011 and set a higher goal for share repurchases even as generic competition and government austerity measures depressed revenue in the second quarter. read more
-
Contributor: Pharmatching.com Blog
Contributor: 07/27/2011 12:00:00 AM EDT
GSK raises dividend; sees recovery in 2012 Published with kind permission of MEDNOUS Tuesday 26 July 2011 GlaxoSmithKline Plc is raising its quarterly dividend by 7% and forecasting an improvement in its profit margin in 2012 following a multi-year restructuring programme and a rebalancing of its sales profile. read more
-
Contributor: Pharmatching.com Blog
Contributor: 07/25/2011 12:00:00 AM EDT
Roche raises earnings outlook even as first-half sales are flat July 21st 2011: The Roche group is raising its outlook for core earnings per share in 2011 despite results for the first half of the year showing that sales, expressed in local currencies, were flat. read more
-
Contributor: Pharmatching.com Blog
Contributor: 07/21/2011 12:00:00 AM EDT
Diversified portfolio boosts Novartis at Q2 Pulished with kind permission of MEDNOUS Novartis’s diversified healthcare portfolio underpinned group sales and profit in the 2011 second quarter with significant contributions made by sales of generic medicines, consumer health products and recently-acquired Alcon Inc. read more
-
Contributor: Pharmatching.com Blog
Contributor: 06/20/2011 12:00:00 AM EDT
Sanofi takes option on hearing technology Published with kind permission of MEDNOUS. Sanofi SA has entered into a two-year research collaboration with a small Netherlands-based company, Audion Therapeutics BV, to develop potential treatments for hearing loss by targeting progenitor cells in the inner ear with small molecule compounds. read more
-
Contributor: Pharmatching.com Blog
Contributor: 06/20/2011 12:00:00 AM EDT
Troubleshooting Biomarker Development Strategies Dr. Gabriele Dallmann, CEO of Pharmatching.com, talks to Kristof Vercruysse, Director Clinical Operations at Ablynx about Troubleshooting Biomarker Development Strategies Listen to Podcast now In this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. read more
| 97 blog results |
|
-
Global Pharmaceutical Distribution 2012
Venue to be Confirmed, Amsterdam, The Netherlands
September 18- 19, 2012 -
Cool Chain Logistics 2013
Congress Center Basel, Basel, Switzerland
January 28- 30, 2013 -
Information Governance & eDiscovery for Pharma, Biotech and Medical Devices
London, UK
June 26- 28, 2012 -
Cold Chain Global Forum 2012
Chicago, IL
September 24- 28, 2012
|
|
|
|
Subscribe by Email
-
ELN - Project & Program Innovations:
The Art of Measuring the ROI of ELNs - Keep it Real: As a project sponsor, business unit owner, or even as a project manager, inevitability you’ll be asked to cut through the hype, the position papers, and promises surrounding ELNs and put together an actual ELN business case. read more
Anthony Chambers | ELN | ELN ROI
-
Ensuring a Change for the Better:
A Revolutionary Paradigm Shift in Big Pharma's Organisational Development: A paradigm is the conceptual framework upon which we build our world; it is built upon past experiences; if we are not willing to make shifts in our paradigms, we will remain stagnate in our growth; a paradigm shift is a change from one way of thinking to another; it is something that does not read more
Big Pharma's Organisational Development | Cristina Falcão | paradigm shift
-
Global Clinical Outsourcing Forum – Avoids Death by PowerPoint with New Format – Round Up: ... read more
clinical outsourcing | global clinical outsourcing | Global Clinical Outsourcing Forum
-
Smooth the Path to Integration in Informatics: With an increasing emphasis on informatics... read more
Informatics | Standards | integration
|
Reach Pharma professionals through cost-effective marketing opportunities to deliver your message, position yourself as a thought leader, and introduce new products, techniques and strategies to the market.
Learn More >> Join today and interact with a vibrant network of pharma professionals, keeping up to date with the pharma industry by accessing our wealth of Pharma articles, videos, online seminars, live conferences and more. Sign Up Today! |
| Pharma IQ, a division of IQPC 2012 All rights reserved. Use of this site constitutes acceptance of our User Agreement and Privacy Policy. Careers With IQPC | Contact Us | Unsubscribe to Bizo | About Us |
|
Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!